

evaluation. I believe that this suggests that artificial intelligence will soon enter the imaging arena in nuclear medicine, an eventuality for which we should be preparing now. A second major trend was seen in multimodal studies in both humans and animals to investigate physiologic and pathophysiological interactions in the brain.

To conclude, I would like to cite Henry N. Wagner, Jr., MD, who, in turn, once quoted Arthur Koestler: "In biology,

structures are slow processes of long duration; what we call functions are fast processes of short duration." Dr. Wagner added that they are all processes—changes in mass as a function of time. This observation leads to the conclusion that the methods we have available in our field for functional, structural, and molecular imaging allow us nothing less than the ability to assess biological processes of different speed and duration *in vivo*.

SNMMI Wagner–Torizuka Fellowships Announced

SNMMI announced on August 23 the recipients of the 2016–2018 SNMMI Wagner–Torizuka Fellowships. This 2-year fellowship, founded in 2008 by Henry N. Wagner, Jr., MD, and Kanji Torizuka, MD, PhD, is designed to provide training and experience in nuclear medicine and molecular imaging for Japanese physicians in the early stages of their careers. "SNMMI is proud to sponsor the Wagner–Torizuka Fellowship. Each year, the program provides 3 outstanding Japanese scientists in the field of nuclear medicine and molecular imaging with 2 years of funding to further their research in the United States under the guidance of current leaders in the field," said Gary L. Dillehay, MD, SNMMI past president and 2014–2016 chair of the SNMMI Awards Committee. The 2016–2018 fellows, who will receive annual stipends of \$24,000, are:

- **Kimiteru Ito, MD, PhD**, Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology (Tokyo, Japan), whose research focuses on associations between the therapeutic efficacy of checkpoint inhibitors and ¹⁸F-FDG PET/CT findings, as well as interim ¹⁸F-FDG PET/CT and prognosis in patients with T-cell lymphoma. Ito is currently a visiting researcher in the molecular imaging and therapy service at the Memorial Sloan–Kettering Cancer Center (New York, NY) under the supervision of Wolfgang Weber, MD.

- **Akira Toriihara, MD, PhD**, Tokyo Medical and Dental University (Japan), whose research interests include development of semiquantitative assessments of SPECT/CT using ⁶⁷Ga-citrate and ¹²³I-ioflupane. Toriihara is studying at Stanford University School of Medicine (CA) in the Department of Radiology's Nuclear Medicine and Molecular Imaging Division under the supervision of Andrei Iagaru, MD.

- **Takuya Toyonaga, MD**, Hokkaido University Graduate School of Medicine (Sapporo, Japan), who is researching ¹¹C-UCB-J as a radioligand for imaging synaptic vesicle glycoprotein 2A and its potential application in Alzheimer disease. Toyonaga is studying at the Yale School of Medicine PET Center (New Haven, CT) under the supervision of Richard Carson, PhD.

The SNMMI Wagner–Torizuka Fellowship program, sponsored by Nihon Medi-Physics Co., Ltd., in Japan, has successfully graduated 24 fellows since its inauguration in 2008. Five fellows are currently studying at host institutions across the United States. Applications and additional information about requirements for the 2017–2019 SNMMI Wagner–Torizuka Fellowship are available online at www.snmmi.org/grants. Applications are due by January 20, 2017. For more information about these and other scholarships, visit www.snmmi.org/grants or contact the SNMMI Development Department at 703-652-6780 or at tellmer@snmmi.org.